Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The protease inhibitor era: an opportunity to improve the quality of care.

Literature DB >> 21416243

The protease inhibitor era: an opportunity to improve the quality of care.

Andrew J Muir.

Abstract

Mesh：

Substances：

Year: 2011 PMID： 21416243 DOI： 10.1007/s10620-011-1674-2

Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199

Keyword Cloud
References

× No keyword cloud information.

8 in total

1. Commentary: Urgently needed: a safe place for self-assessment on the path to maintaining competence and improving performance.

Authors: Bruce J Bellande; Zev M Winicur; Kathleen M Cox
Journal: Acad Med Date: 2010-01 Impact factor: 6.893

2. Hepatitis C treatment completion rates in routine clinical care.

Authors: Adeel A Butt; Kathleen A McGinnis; Melissa Skanderson; Amy C Justice
Journal: Liver Int Date: 2009-11-04 Impact factor: 5.828

3. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Authors: Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; David Pound; Mitchell N Davis; Joseph S Galati; Stuart C Gordon; Natarajan Ravendhran; Lorenzo Rossaro; Frank H Anderson; Ira M Jacobson; Raymond Rubin; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Eirum Chaudhri; Janice K Albrecht
Journal: Lancet Date: 2010-08-06 Impact factor: 79.321

The protease inhibitor era: an opportunity to improve the quality of care.

1. Commentary: Urgently needed: a safe place for self-assessment on the path to maintaining competence and improving performance.

2. Hepatitis C treatment completion rates in routine clinical care.

3. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

4. Quality of care in patients with chronic hepatitis C virus infection: a cohort study.

Review 5. Efficacy of chronic hepatitis C therapy in community-based trials.

6. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

7. Diagnosis, management, and treatment of hepatitis C: an update.

8. Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use.